MedTrace Logo

A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

NCT06738251 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 402

Last updated 2025-07-17

No results posted yet for this study

Summary

To evaluate the efficacy and safety of SHR-A2102 for injection versus Investigator-selected Therapy in patients with Locally advanced or Metastatic Urothelial Carcinoma who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.

Conditions

  • Advanced Urothelial Carcinoma

Interventions

DRUG

SHR-A2102 for Injection

SHR-A2102 for Injection.

DRUG

Docetaxel Injection

Docetaxel Injection.

DRUG

Paclitaxel Injection

Paclitaxel Injection.

DRUG

Gemcitabine Hydrochloride for Injection

Gemcitabine Hydrochloride for Injection.

DRUG

Pemetrexed Disodium for Injection

Pemetrexed Disodium for Injection.

Sponsors & Collaborators

  • Shanghai Hengrui Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-12
Primary Completion
2026-07-31
Completion
2027-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06738251 on ClinicalTrials.gov